Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathways and targeting avenues of BRAF in non-small cell lung cancer.

Expert opinion on therapeutic targets - 1 Jul 2024

Imyanitov Evgeny N, Mitiushkina Natalia V, Kuligina Ekatherina Sh, Tiurin Vladislav I, Venina Aigul R

Abstract excerpt

INTRODUCTION: BRAF is a serine-threonine kinase implicated in the regulation of MAPK signaling cascade. BRAF mutation-driven activation occurs in approximately 2-4% of treatment-naive non-small cell carcinomas (NSCLCs). BRAF upregulation is also often observed in tumors with acquired resistance to receptor tyrosine kinase inhibitors (TKIs). AREAS COVERED: This review describes the spectrum of BRAF mutations and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to MAP Kinase Signaling System

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38941191
DOI: 10.1080/14728222.2024.2374742

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathways and targeting avenues of BRAF in non-small cell lung cancer.PMID 38941191Read ↗

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read ↗

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Advances in anti-BRAF therapies for lung cancer.Semantic proximity Read ↗

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.Semantic proximity Read ↗

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.Semantic proximity Read ↗

[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

A BRAF new world.Semantic proximity Read ↗

[Mutation of the BRAF genes in non-small cell lung cancer].Semantic proximity Read ↗

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeSemantic proximity Read ↗

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Semantic proximity Read ↗

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.